08:00 , Nov 11, 2013 |  BC Week In Review  |  Clinical News

ALF-5755: Phase II data

A double-blind, European Phase II trial in 57 patients with HBV- and autoimmune-related acute-on-chronic liver disease or acute liver disease showed that 10 mg IV ALF-5755 every 12 hours for 3 days missed the primary...
08:00 , Dec 22, 2008 |  BC Week In Review  |  Clinical News

rhHIP/PAP regulatory update

EMEA's Committee for Orphan Medicinal Products (COMP) issued a positive opinion to grant Orphan Drug designation for Alfact's rhHIP/PAP to treat acute liver failure. The recombinant human hepatocarcinoma-intestine-pancreas and pancreatic associated protein will begin Phase...
07:00 , Oct 9, 2006 |  BC Week In Review  |  Company News

Cellectis management update

Cellectis S.A., Romainville Cedex, France   Business: Genomics   Hired: Marc Le Bozec as CFO, formerly COO at Alfact Innovation   ...
01:18 , Oct 3, 2006 |  BC Extra  |  Company News

Cellectis names Le Bozec CFO

Cellectis (Romainville, France) hired Marc Le Bozec as CFO. He was formerly COO at Alfact Innovation (Paris, France). Cellectis is developing its Meganuclease technology to repair or replace damaged or inherited genes in vivo....